The stock of Regenxbio Inc (NASDAQ:RGNX) is a huge mover today! About 91,500 shares traded hands. Regenxbio Inc (NASDAQ:RGNX) has risen 9.49% since March 2, 2016 and is uptrending. It has outperformed by 1.24% the S&P500.
The move comes after 7 months positive chart setup for the $408.20M company. It was reported on Oct, 5 by Barchart.com. We have $29.85 PT which if reached, will make NASDAQ:RGNX worth $395.95 million more.
Analysts await Regenxbio Inc (NASDAQ:RGNX) to report earnings on November, 3. They expect $-0.66 EPS, up 56.58% or $0.86 from last year’s $-1.52 per share. After $-0.55 actual EPS reported by Regenxbio Inc for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.
Regenxbio Inc (NASDAQ:RGNX) Ratings Coverage
Out of 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Regenxbio has been the topic of 4 analyst reports since October 12, 2015 according to StockzIntelligence Inc. Chardan Capital Markets initiated Regenxbio Inc (NASDAQ:RGNX) on Tuesday, October 20 with “Buy” rating. Bank of America initiated the stock with “Buy” rating in Monday, October 12 report. The company was initiated on Monday, October 12 by Piper Jaffray. Morgan Stanley initiated the stock with “Overweight” rating in Tuesday, October 13 report.
According to Zacks Investment Research, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.”
More important recent Regenxbio Inc (NASDAQ:RGNX) news were published by: Seekingalpha.com which released: “IPO Preview: REGENXBIO Inc.” on September 17, 2015, also Bizjournals.com published article titled: “Venture-backed Md. biotech files for IPO”, Businesswire.com published: “ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale …” on May 24, 2016. More interesting news about Regenxbio Inc (NASDAQ:RGNX) was released by: Globenewswire.com and their article: “REGENXBIO Provides Update on Lead Gene Therapy Development Programs” with publication date: July 05, 2016.
RGNX Company Profile
REGENXBIO Inc., incorporated on July 16, 2008, is a biotechnology company. The Firm is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Company’s AAV gene delivery platform (NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). The Company’s NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. NAV Vectors have demonstrated stable expression in animals for over eight years. In addition, AAV8 vectors have demonstrated stable expression for over four years in a clinical trial for the treatment of hemophilia B. The Firm develops products for various indications, including metabolic, neurodegenerative and retinal diseases. The Company’s therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.